Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Anixa Biosciences Inc

ANIX ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$2.71

▲ +1.12%

Market Cap $94.21M · Vol 25.93K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$94.21M

Micro Cap

Div Yield

N/A

EPS Growth

+2.94%

YoY

RSI (14)

47.03

Momentum

Beta

0.48

vs Market

52W High

$5.44

50.74% below

52W Low

$2.32

15.52% above

Volume

25.93K

Avg 86.32K

P/B

8.99

Price-to-book

ROE

-62.16%

Return on equity

Free Float

92.71%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Anixa Biosciences Inc (ANIX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ANIX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.07%

+0.37%

-23.88%

-5.90%

YTD

-13.14%

-35.17%

-13.42%

-37.41%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-11,028,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-62.16%
ROA · ROIC	-58.55% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	8.99
P/FCF	N/A
EPS Growth	+2.94%
Outstanding Shares	34.76M

Technical Indicators

50-Day SMA	$3.01
200-Day SMA	$2.97
RSI (14)	47.03
Beta	0.48
52-Week High	$5.44
52-Week Low	$2.32

Volume Today	25.93K
Avg Daily Volume (30D)	86.32K
Relative Volume	0.30x
Volatility (10D)	47.02
Volatility (30D)	48.64
Free Float	92.71%

Analyst Consensus

BUY

Current Price $2.71

Mean Target $9.75

52W Low$2.32 52W High$5.44

Current

Target

$2.32 $5.44

Current Analyst target

+259.78% upside potential · 4 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001S5Q1P7

ISINUS03528H1095

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateJan 11, 2027

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -0.25% ARGX.BR argenx SE +0.82% ARGX argenx SE +2.34% 2269.HK WuXi Biologics (Cayman) Inc. -1.30% GMAB Genmab A/S +1.28%

Company Profile

Anixa Biosciences, Inc. is a biotechnology company. The Company is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. It is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.